ORIONIS
DEAD

Serial Number

88760741

Owner

Orionis Biosciences Inc.

Attorney

Rachelle A. Dubow, Esq.

Filing Date

Jan 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ORIONIS Trademark

Serial Number: 88760741

ORIONIS is a trademark filed by Orionis Biosciences Inc. on January 15, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Orionis Biosciences Inc. (8 trademarks)

Waltham, MA 02451

Entity Type: 03

Trademark Details

Filing Date

January 15, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorder; cytokines, namely, reagents for scientific and research use; pharmaceutical preparations, namely, cytokine inhibitory drugs; Therapeutic pharmaceutical and diagnostic preparations, namely, antibodies, cytokines, antigens, enzymes, immunoconjugates for treatment of cancer, immunological conditions, metabolic disorders; Biochemical and small molecule preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases

Diagnostic, biological and chemical reagents for scientific and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical or biological ingredients for use in the manufacture of pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases

Development of new technology for others in the field of biotechnology; scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; biotechnical research; technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; research and development of pharmaceuticals for others; scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 12, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 12, 2024 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 27, 2023 GNFN
FINAL REFUSAL E-MAILED
Oct 27, 2023 GNFR
FINAL REFUSAL WRITTEN
Oct 27, 2023 CNFR
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 27, 2023 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 31, 2023 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 1, 2022 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 29, 2021 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 23, 2021 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 10, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 10, 2020 GNSL
SUSPENSION LETTER WRITTEN
Aug 10, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 20, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 20, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 20, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 25, 2020 GNRN
NON-FINAL ACTION E-MAILED
Mar 25, 2020 GNRT
NON-FINAL ACTION WRITTEN
Mar 25, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 24, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 22, 2020 NWOS
NEW APPLICATION ENTERED
Jan 18, 2020 NWAP